<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2017.62017</article-id><article-id pub-id-type="publisher-id">TCM-20661</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20170200000_23348633.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  五酯胶囊对肾移植术后早期他克莫司药代动力学和肝肾功能的影响
  Effect of Wuzhi Capsule on the Pharmacokinetics and Liver Function, Renal Function of Tacrolimus
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>雷</surname><given-names>慧君</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>颖鎏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>蟠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晶晶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>武</surname><given-names>鹏浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>慧青</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>添</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>路</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>万雷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>郑州大学基础医学院，河南 郑州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>ywl@zzu.edu.cn(杨万)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>05</month><year>2017</year></pub-date><volume>06</volume><issue>02</issue><fpage>98</fpage><lpage>103</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：五味子，木兰科的多年生草本植物北五味子属的成熟果实，其在许多国家广泛用作滋补类营养品和恢复性加强肝脏及其他器官的功能。五酯胶囊，一种五味子醇提制剂，是一个著名的中药，在中国广泛使用。五酯胶囊及其活性成分木酚素/木脂素显著保护肝损伤，在中国通常与TAC联合应用来防止药物引起的肝炎。本研究旨在探讨五酯胶囊对肾移植术后早期他克莫司血药浓度和肝肾功能的影响。方法：回顾性研究113名肾移植受者，未用五酯胶囊者55人，匹配年龄和性别后应用五酯胶囊者58人，所有患者接受Tac + MMF + Pred三联免疫抑制治疗。检测3天、7天和30天时Tac的血药浓度的变化，使用微粒酶免疫测定(MEIA)法。与此同时，测试所有患者的肝脏、肾脏功能。肝功能、肾功能、全血他克莫司浓度进行了两组之间的分析比较。结果：我们发现五酯胶囊可以显著提高3天、7天和30天时TAC血药浓度。3天、7天和30天时，五酯胶囊组全血Tac浓度平均增加了40.1%、23.3%、15.0%。更重要的是，直接胆红素也显著降低。两组之间其他的肝肾功能指标没有显著的差异(P &gt; 0.05)。结论：五酯胶囊可以显著提高肾移植受者的Tac血药浓度，且具有保护肝脏的作用，没有明显的不良反应。 Objective: Fructus Schisandrae, the ripe fruits of perennial plant of Schisandra chinensis (Turcz.) Baill, perennial herb of family Magnoliaceae, is widely used as a restorative, tonic nutrition to enhance the function of liver and other organs in many countries. Wuzhi capsule, an ethanol extract preparation of Fructus Schisandrae, is a well-known herbal medicine widely used in China. Wuzhi capsule and its active lignans significantly protect liver injury, and are often prescribed with TAC to prevent drug-induced hepatitis in China. This study aimed to investigate the effects of Wuzhi capsule on blood concentration of tacrolimus and liver function, renal function after renal transplantation. Methods: One hundred and thirteen renal transplant recipients were randomly assigned to two groups, i.e., 58 in the WC group and 55 in the control group. All patients received Tac + MMF + Pred triple immunosuppressive therapy. One month was taken as one therapeutic course. Changes of the blood concentration of Tac were detected 3, 7, 30 d after medication in the two groups using microparticle enzyme immune assay (MEIA). Meanwhile, the liver and kidney functions were tested. Liver function, renal function, and whole-blood concentrations of tacrolimus were analyzed to compare between the two groups. Results: We found that WZ capsule could significantly increase TAC blood concentration at 3, 7, 30 d. At 3, 7, 30 d after the application of WC capsule, the blood Tac concentration increased 40.1%, 23.3%, 15.0% averagely. More importantly, serum DBIL was also remarkably reduced. There was no significant difference in the liver and renal functions between the two groups (P &gt; 0.05). Conclusion: WC capsule could significantly increase the blood Tac concentration of renal transplant recipients with liver protection, and has no obvious adverse reaction. 
  
 
</p></abstract><kwd-group><kwd>五酯胶囊，他克莫司，药代动力学，肝功能，肾功能, Wuzhi Capsule</kwd><kwd> Tacrolimus</kwd><kwd> Pharmacokinetics</kwd><kwd> Liver Function</kwd><kwd> Renal Function</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>五酯胶囊对肾移植术后早期他克莫司药代动力学和肝肾功能的影响<sup> </sup></title><p>雷慧君<sup>*</sup>，罗颖鎏<sup>*</sup>，苏蟠<sup>*</sup>，李晶晶，武鹏浩，李慧青，王添，路静<sup>#</sup>，杨万雷<sup>#</sup></p><p>郑州大学基础医学院，河南 郑州</p><disp-formula id="hanspub.20661-formula87"><graphic xlink:href="http://html.hanspub.org/file/11-2270190x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年5月4日；录用日期：2017年5月22日；发布日期：2017年5月25日</p><disp-formula id="hanspub.20661-formula88"><graphic xlink:href="http://html.hanspub.org/file/11-2270190x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：五味子，木兰科的多年生草本植物北五味子属的成熟果实，其在许多国家广泛用作滋补类营养品和恢复性加强肝脏及其他器官的功能。五酯胶囊，一种五味子醇提制剂，是一个著名的中药，在中国广泛使用。五酯胶囊及其活性成分木酚素/木脂素显著保护肝损伤，在中国通常与TAC联合应用来防止药物引起的肝炎。本研究旨在探讨五酯胶囊对肾移植术后早期他克莫司血药浓度和肝肾功能的影响。方法：回顾性研究113名肾移植受者，未用五酯胶囊者55人，匹配年龄和性别后应用五酯胶囊者58人，所有患者接受Tac + MMF + Pred三联免疫抑制治疗。检测3天、7天和30天时Tac的血药浓度的变化，使用微粒酶免疫测定(MEIA)法。与此同时，测试所有患者的肝脏、肾脏功能。肝功能、肾功能、全血他克莫司浓度进行了两组之间的分析比较。结果：我们发现五酯胶囊可以显著提高3天、7天和30天时TAC血药浓度。3天、7天和30天时，五酯胶囊组全血Tac浓度平均增加了40.1%、23.3%、15.0%。更重要的是，直接胆红素也显著降低。两组之间其他的肝肾功能指标没有显著的差异(P &gt; 0.05)。结论：五酯胶囊可以显著提高肾移植受者的Tac血药浓度，且具有保护肝脏的作用，没有明显的不良反应。</p><p>关键词 :五酯胶囊，他克莫司，药代动力学，肝功能，肾功能</p><disp-formula id="hanspub.20661-formula89"><graphic xlink:href="http://html.hanspub.org/file/11-2270190x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>作为新一代的钙调蛋白磷酸酶抑制剂，他克莫司具有良好的免疫抑制作用和较小的不良反应发生率，在临床实际中有着良好的应用前景。但其本身固有的诸如肾毒性、胃肠道反应、高血糖、高血压、高血脂、感染増加等不良反应及为维持有效血药浓度而长期服药带来的高昂费用使得不少患者被迫改变免疫抑制方案或中途自行停药，进而使得治疗效果不理想和延误病情，成为制约患者得到有效治疗的瓶颈。他克莫司主要在肠吸收，主要在肝脏和肠道代谢，任何影响药物肠道吸收及CYP3A活性的药物均能影响TAC血药浓度 [<xref ref-type="bibr" rid="hanspub.20661-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref2">2</xref>] ，在肠道和肾脏任何影响药物肠道吸收及P-gp的药物也均能影响TAC血药浓度 [<xref ref-type="bibr" rid="hanspub.20661-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref4">4</xref>] 。另外，肾移植术后患者服用药物种类多，而且多数药物在肝脏中代谢，药物性肝损害发生率相对较高，常需保肝护肝治疗。</p><p>五酯胶囊是一种肝细胞损伤阻滞剂，有效成分具有营养心肌、保肝护肝、安神镇定、抗癌、拮抗血小板活化因子(PAF)和抑制醛糖还原酶等多种作用，被较多的应用于急、慢性肝炎、肝硬化、肝损伤、肝移植等各种肝脏疾病的治疗之中，也常被应用于肾移植术后保肝护肝治疗 [<xref ref-type="bibr" rid="hanspub.20661-ref5">5</xref>] - [<xref ref-type="bibr" rid="hanspub.20661-ref12">12</xref>] 。近年来有报道显示五酯胶囊与他克莫司合用可有效提升他克莫司在全血中的血药浓度，进而可有效减低患者使用他克莫司的剂量和费用支出 [<xref ref-type="bibr" rid="hanspub.20661-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref14">14</xref>] ，从而同时也降低了他克莫司引发的不良反应发生风险。在我国，肝移植和肾移植患者在服用他克莫司的同时添加五酯胶囊口服来提升他克莫司血药浓度己经非常普遍 [<xref ref-type="bibr" rid="hanspub.20661-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref17">17</xref>] ，多数移植受者甚至将此药物组合作为节约他克莫司用量的方法而长期联合服用。本研究探讨口服五酯胶囊对肾移植受者他克莫司血药浓度以及主要生化指标的影响，探讨在保证安全和有效的前提下减少他克莫司胶囊的摄入量，进而减轻他克莫司的毒副作用、经济负担和提高患者治疗的依从性，为当前临床治疗寻求一种安全、有效，且经济、方便的免疫抑制方案提供理论依据。</p></sec><sec id="s4"><title>2. 方法</title><sec id="s4_1"><title>2.1. 观察对象</title><p>回顾性分析113名以他克莫司为基础免疫抑制剂的肾移植受者，从郑州大学第一附属医院收集55名未用五酯胶囊的患者，与58名使用五酯胶囊的患者相比较。两组之间的性别、年龄等相匹配。本研究所有入选患者均签署知情同意书。本研究经郑州大学伦理委员会批准。对符合研究要求的受者按术后D3d、D7d、D30d收集以下有关指标：性别、年龄、身高、体质量、民族、透析时间等、TAC服药量和浓度，以及谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBIL)、直接胆红素(DBIL)、间接胆红素(IBIL)、总蛋白(TP)、血清肌酐(SCr)和尿素氮(BUN)。其中，肝功能指标包括AST、ALT、TBIL、DBIL、IBIL和TP；肾功能指标包括SCr和BUN。</p></sec><sec id="s4_2"><title>2.2. 三联用药方案及五酯胶囊剂量</title><p>所有入选患者术后均使用他克莫司作为基础免疫抑制剂，联合使用骁悉(MMF)和糖皮质激素。术后他克莫司起始剂量根据体重给药为0.1 mg/(Kg*d)，开始服用他克莫司3天后首次检测血药浓度，以后根据病人实际临床效果和反应参考血药浓度检测结果调整剂量，参考的血药浓度检测结果为术后1个月以内血药谷浓度C<sub>0</sub>维持在6~15 ng/ml左右，1~3个月维持在8~15 ng/ml，4~6个月维持在7~12 ng/ml，7~12个月维持在5~10 ng/ml，12个月以后维持在7~9 ng/ml (2010年版《他克莫司在临床肾移植中的应用指南》)。每日量分早晚两次间隔12 h服用。五酯胶囊每次2粒，每天2次。</p></sec><sec id="s4_3"><title>2.3. 统计学方法</title><p>所有数据采用SPSS 17.0 统计软件包进行处理，计量资料用均数&#177;标准差表示，组间比较用单因素方差分析。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 中原地区人口学特征</title><p>见表1。</p></sec><sec id="s5_2"><title>3.2. 五酯胶囊对他克莫司血药浓度的影响</title><p>肾移植患者口服五酯胶囊能够明显提升术后早期3天、7天和30天的他克莫司全血谷浓度。上表显</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics population of the central Chin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >病例总数(N = 113)</th><th align="center" valign="middle" >未用五酯胶囊(N = 55)</th><th align="center" valign="middle" >合用五酯胶囊(N = 58)</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >Male (%)</td><td align="center" valign="middle" >80 (70.8)</td><td align="center" valign="middle" >39 (70.9)</td><td align="center" valign="middle" >41 (70.6)</td><td align="center" valign="middle" >0.597</td></tr><tr><td align="center" valign="middle" >Female (%)</td><td align="center" valign="middle" >33 (29.2)</td><td align="center" valign="middle" >16 (29.1)</td><td align="center" valign="middle" >17 (29.3)</td><td align="center" valign="middle" >0.623</td></tr><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" >37.1 &#177; 10.1</td><td align="center" valign="middle" >36.2 &#177; 10.2</td><td align="center" valign="middle" >42.1 &#177; 9.9</td><td align="center" valign="middle" >0.314</td></tr><tr><td align="center" valign="middle" >Height (cm)</td><td align="center" valign="middle" >166.37 &#177; 7.86</td><td align="center" valign="middle" >166.18 &#177; 7.89</td><td align="center" valign="middle" >166.59 &#177; 7.32</td><td align="center" valign="middle" >0.249</td></tr><tr><td align="center" valign="middle" >Weight (kg)</td><td align="center" valign="middle" >58.37 &#177; 10.35</td><td align="center" valign="middle" >58.73 &#177; 11.56</td><td align="center" valign="middle" >57.87 &#177; 10.58</td><td align="center" valign="middle" >0.396</td></tr><tr><td align="center" valign="middle" >BSA (m<sup>2</sup>)</td><td align="center" valign="middle" >1.61 &#177; 0.17</td><td align="center" valign="middle" >1.60 &#177; 0.18</td><td align="center" valign="middle" >1.62 &#177; 0.32</td><td align="center" valign="middle" >0.243</td></tr></tbody></table></table-wrap><p>表1. 中原地区人口学特征</p><p>Reported age and baseline weight are those measured at the time of transplant and are mean &#177; SD. BSA = 0.0061 &#215; height (in cm) + 0.0128 &#215; weight (in kg) − 0.1529.</p><p>示：3天、7天、30天时，口服五酯胶囊的患者的他克莫司的浓度分别为15.64 &#177; 6.63 ng/ml、13.59 &#177; 4.69 ng/ml、11.89 &#177; 2.78 ng/ml，明显高于未同时口服五酯胶囊的患者的他克莫司的浓度(11.16 &#177; 6.69 ng/ml、11.02 &#177; 5.53 ng/ml、10.34 &#177; 4.96 ng/ml)。</p></sec><sec id="s5_3"><title>3.3. 五酯胶囊对肾移植受者肝肾功能指标的影响</title><p>口服五酯胶囊能够显著降低DBIL的值(与未合用五酯胶囊的2.15 &#177; 1.59相比，合用五酯胶囊患者的DBIL值降为1.74 &#177; 0.61)，P = 0.02；另外，我们还发现，五酯胶囊具有轻微降低AST的趋势(20.07 &#177; 15.55 vs. 21.19 &#177; 15.10，P = 0.71)。尿素氮BUN和血肌酐在五酯胶囊组也具有降低的趋势，不过无统计学意义。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>大量临床实践证实在种类繁多的免疫抑制药物之中，他克莫司以其良好的免疫抑制效能和相对较少的不良反应发生率被大量应用于临床 [<xref ref-type="bibr" rid="hanspub.20661-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref20">20</xref>] 。在我国，肝脏移植和肾脏移植在器官移植手术中占有较高的比例，故免疫抑制剂的使用成为提高移植的肝脏和肾脏的存活率的有力保障。肾移植患者合用药物众多且需要终身服用相关药物，而大多数药物以及他克莫司本身都具有一定程度的肝毒性，因此很多患者也需要同时服用护肝药。</p><p>五酯胶囊是由从五味子中提取的木脂素衍生物，经醇提取后获得其活性成分精制而成的中成药复方制剂，其主要成分为五味子甲素(Sch A)，另外还有一定量的五味子乙素成分。五酯胶囊是一种肝细胞损伤阻滞剂，有效成分具有营养心肌、保肝护肝、安神镇定、抗癌、拮抗血小板活化因子(PAF)和抑制醛糖还原酶等多种作用，被较多的应用于急、慢性肝炎、肝硬化、肝损伤、肝移植等各种肝脏疾病的治疗之中，也常被应用于肾移植术后保肝护肝治疗 [<xref ref-type="bibr" rid="hanspub.20661-ref5">5</xref>] - [<xref ref-type="bibr" rid="hanspub.20661-ref12">12</xref>] 。</p><p>合用他克莫司和五酯胶囊来提升他克莫司血药浓度已成为一种具有巨大吸引力的治疗策略，部分研究也报到证实二者联用可以在确保免疫抑制的效能情况下显著的提升他克莫司在全血中的血药浓度水平 [<xref ref-type="bibr" rid="hanspub.20661-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref22">22</xref>] 。本研究发现(见本文表2)：肾移植患者口服五酯胶囊能够明显提升术后早期3天、7天和30天的他克莫司全血谷浓度。这就提示我们，在保证安全和有效的前提下，我们可以适度减少他克莫司胶囊的摄入量，这样既减轻了他克莫司的毒副作用，也同时减轻了病人家庭的经济负担，能相应提高患者治疗的依从性，这应该一种当前临床治疗安全、有效，且经济、方便的免疫抑制方案。</p><p>五酯胶囊经醇提获得的脂溶性活性部位，是一种拮抗肝细胞损伤的药物，有助于加速肝细胞的再生、促进肝细胞蛋白质的合成，还可通过提高NADPH-细胞色素Ｃ还原酶、苯并芘羟化酶等的活性，拮抗氧化自由基，阻断各种有毒物质如病毒、FK506等对肝细胞膜的损伤 [<xref ref-type="bibr" rid="hanspub.20661-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.20661-ref24">24</xref>] 。本试验统计发现，口服五酯胶囊能够显著降低DBIL的值(与未合用五酯胶囊的2.15 &#177; 1.59相比，合用五酯胶囊患者的DBIL值降为1.74 &#177; 0.61)，从而证实其对改善肝功能作用(见本文表3)。另外，我们还发现，五酯胶囊具有轻微降低</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Wuzhi capsule on the influence of tacrolimus blood concentration</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" >Mean &#177; SD</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >浓度3天<sup>**</sup></td><td align="center" valign="middle" >五酯</td><td align="center" valign="middle" >15.64 &#177; 6.63</td><td align="center" valign="middle" >0.0012</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >无五酯</td><td align="center" valign="middle" >11.16 &#177; 6.69</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >浓度7天<sup>**</sup></td><td align="center" valign="middle" >五酯</td><td align="center" valign="middle" >13.59 &#177; 4.69</td><td align="center" valign="middle" >0.0060</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >无五酯</td><td align="center" valign="middle" >11.02 &#177; 5.53</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >浓度1月<sup>*</sup></td><td align="center" valign="middle" >五酯</td><td align="center" valign="middle" >11.89 &#177; 2.78</td><td align="center" valign="middle" >0.041</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >无五酯</td><td align="center" valign="middle" >10.34 &#177; 4.96</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 五酯胶囊对他克莫司血药浓度的影响</p><p><sup>*</sup>: P &lt; 0.05. <sup>**</sup>: P &lt; 0.01.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Wuzhi capsule influences on the liver and kidney functio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >合用</th><th align="center" valign="middle" >未合用</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >TBIL</td><td align="center" valign="middle" >10.37 &#177; 4.56</td><td align="center" valign="middle" >10.60 &#177; 6.45</td><td align="center" valign="middle" >0.82</td></tr><tr><td align="center" valign="middle" >DBIL<sup>*</sup></td><td align="center" valign="middle" >1.74 &#177; 0.61</td><td align="center" valign="middle" >2.15 &#177; 1.59</td><td align="center" valign="middle" >0.02</td></tr><tr><td align="center" valign="middle" >IBIL</td><td align="center" valign="middle" >8.63 &#177; 4.07</td><td align="center" valign="middle" >8.45 &#177; 5.25</td><td align="center" valign="middle" >0.83</td></tr><tr><td align="center" valign="middle" >TP</td><td align="center" valign="middle" >63.53 &#177; 7.48</td><td align="center" valign="middle" >62.34 &#177; 7.15</td><td align="center" valign="middle" >0.42</td></tr><tr><td align="center" valign="middle" >ALT</td><td align="center" valign="middle" >24.01 &#177; 20.88</td><td align="center" valign="middle" >21.00 &#177; 14.25</td><td align="center" valign="middle" >0.45</td></tr><tr><td align="center" valign="middle" >AST</td><td align="center" valign="middle" >20.07 &#177; 15.55</td><td align="center" valign="middle" >21.19 &#177; 15.10</td><td align="center" valign="middle" >0.71</td></tr><tr><td align="center" valign="middle" >SCr</td><td align="center" valign="middle" >121.47 &#177; 106.45</td><td align="center" valign="middle" >137.91 &#177; 111.52</td><td align="center" valign="middle" >0.43</td></tr><tr><td align="center" valign="middle" >BUN</td><td align="center" valign="middle" >9.72 &#177; 6.63</td><td align="center" valign="middle" >11.50 &#177; 7.34</td><td align="center" valign="middle" >0.18</td></tr></tbody></table></table-wrap><p>表3. 五酯胶囊对肝肾功能指标的影响</p><p><sup>*</sup>: P &lt; 0.05.</p><p>AST的趋势。尿素氮BUN和血肌酐是评价肾功能的重要参考指标，我们发现五酯胶囊具有降低二者的趋势，不过无统计学意义，这在一定程度上说明其对肾功能也具有保护作用(详见本文表3)。</p></sec><sec id="s7"><title>5. 结论</title><p>五酯胶囊可以显著提高肾移植受者的Tac血药浓度，且具有保护肝脏的作用，没有明显的不良反应。</p></sec><sec id="s8"><title>文章引用</title><p>雷慧君,罗颖鎏,苏 蟠,李晶晶,武鹏浩,李慧青,王 添,路 静,杨万雷. 五酯胶囊对肾移植术后早期他克莫司药代动力学和肝肾功能的影响Effect of Wuzhi Capsule on the Pharmacokinetics and Liver Function, Renal Function of Tacrolimus[J]. 中医学, 2017, 06(02): 98-103. http://dx.doi.org/10.12677/TCM.2017.62017</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.20661-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Christians, U., Jacobsen, W., Benet, L.Z., et al. (2002) Mechanism of Clinically Relevant Drug Interactions Associated with Tacrolimus. Clinical Pharmacokinetics, 41, 813-851. &lt;br&gt;https://doi.org/10.2165/00003088-200241110-00003</mixed-citation></ref><ref id="hanspub.20661-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Iwaski, K. (2007) Metabolism of Tacrolimus (FK506) and Recent Topics in Clinical Pharmacokinetics. Drug Metabolism and Pharmacokinetics, 22, 328-335. &lt;br&gt;https://doi.org/10.2133/dmpk.22.328</mixed-citation></ref><ref id="hanspub.20661-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wakasugi, H., Yano, I., Ito, T., et al. (1998) Effect of Clarithromycin on Renal Excretion of Digoxin: Interaction with P-Glycoprotein. Clinical Pharmacology &amp; Therapeutics, 64, 123-128.</mixed-citation></ref><ref id="hanspub.20661-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Greiner, B., Eichelbaum, M., Fritz, P., et al. (1999) The Role of Intestinal P-Glycoprotein in the Interaction of Digoxin and Rifampin. Journal of Clinical Investigation, 104, 147-153. &lt;br&gt;https://doi.org/10.1172/JCI6663</mixed-citation></ref><ref id="hanspub.20661-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Park, J.Y., Shin, H.K., Choi, Y.W., et al. (2009) Gomisin A Induces Ca2+-Dependent Activation of eNOS in Human Coronary Artery Endothelial Cells. Journal of Ethnopharmacology, 125, 291-296.</mixed-citation></ref><ref id="hanspub.20661-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Park, J.Y., Shin, H.K., Lee, Y.J., et al. (2009) The Mechanism of Vasorelaxation Induced by Schisandra chinesis Extract in Rat Thoracic Aorta. Journal of Ethnopharmacology, 121, 69-73.</mixed-citation></ref><ref id="hanspub.20661-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chiu, P.Y., Tang, M.H., Mak, D.H., et al. (2003) Hepatoprotective Mechanism of Schisandrin B: Role of Mitochondrial Glutathione Antioxidant Status and Heat Shock Proteins. Free Radical Biology &amp; Medicine, 35, 368-380.</mixed-citation></ref><ref id="hanspub.20661-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yan, F., Zhang, Q.Y., Jiao, L., et al. (2009) Synergistic Hepatoprotective Effect of Schisandrae lignans with Astragalus Polysaccharides on Chronic Liver Injury in Rats. Phytomedicine, 16, 805-813.</mixed-citation></ref><ref id="hanspub.20661-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Huang, F., Xiong, Y., Xu, L., et al. (2007) Sedative and Hypnotic Activities of the Ethanol Fraction from Fructus Schisandrae in Mice and Rats. Journal of Ethnopharmacology, 110, 471-475.</mixed-citation></ref><ref id="hanspub.20661-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Huang, X., Song, F., Liu, Z., et al. (2007) Studies on Lignin Constituents from Schisandra chinensis (Turcz.) Baill. Fruits Using High-Performance Liquid Chromatography/Electrospray Ionization Multiple-Stage Tandem Mass Spectrometry. Mass Spectrom, 42, 1148-1161. &lt;br&gt;https://doi.org/10.1002/jms.1246</mixed-citation></ref><ref id="hanspub.20661-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, W.L., Huang, S.X., Wang, R.R., et al. (2008) Nortriterpenoids and Lignans from Schisandra sphenanthera. Phytochemistry, 69, 2862-2866.</mixed-citation></ref><ref id="hanspub.20661-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Xu, M., Wang, G., Xie, H., et al. (2005) Determination of Schizandrin in Rat Plasma by High-Performance Liquid Chromatography-Mass Spectrometry and Its Application in Rat Pharmacokinetic Studies. Journal of Chromatography, B, Analytical Technologies in the Biomedical and Life Sciences, 828, 55-61.</mixed-citation></ref><ref id="hanspub.20661-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">谢申平, 晏强, 陈怀周, 等. 五酯胶囊在肾移植术后的临床应用研究[J]. 中国中西医结合杂志, 2011, 31(9): 1213- 1215.</mixed-citation></ref><ref id="hanspub.20661-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">辛华委, 李馨, 吴笑春, 等. 五酯胶囊与他克莫司合用对肾移植受者的成本与效果评估研究[J]. 中国临床药理学杂志, 2011, 27(4): 295-298.</mixed-citation></ref><ref id="hanspub.20661-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">郭晓伟, 陈刚, 朱兰, 等. 五酯胶囊对肾移植受者他克莫司血药浓度的影响[J]. 华中技大学学报(医学版), 2011, 40(1): 95-97.</mixed-citation></ref><ref id="hanspub.20661-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">蒋进发, 魏思东, 陈国勇. 五酯胶囊对肝移植受者他克莫司浓度的影响[J]. 中国临床药理学杂志, 2012, 28(6): 411-413.</mixed-citation></ref><ref id="hanspub.20661-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">吴静. 他克莫司联合五酯软胶囊治疗膜性肾病的临床观察[D]: [硕士学位论文]. 河南: 河南中医学院, 2013.</mixed-citation></ref><ref id="hanspub.20661-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Adam, R., Karam, V., Delvart, V., et al. (2015) Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry. American Journal of Transplantation, 15, 1267-1282. &lt;br&gt;https://doi.org/10.1111/ajt.13171</mixed-citation></ref><ref id="hanspub.20661-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Souto-Rodriguez, R., Molina-Perez, E., Castroagudin, J.F., et al. (2014) Differences in the Incidence and Clinical Evolution of Early Neurotoxicity after Liver Transplantation Based on Tacrolimus Formulation Used in the Immunosuppressive Induction Protocol. Transplantation Proceedings, 46, 3117-3120.</mixed-citation></ref><ref id="hanspub.20661-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Thölking, G., Fortmann, C., Koch, R., et al. (2014) The Tacrolimus Metabolism Rate Influences Renal Function after Kidney Transplantation. PLoS ONE, 9, e111128. &lt;br&gt;https://doi.org/10.1371/journal.pone.0111128</mixed-citation></ref><ref id="hanspub.20661-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">陈夏, 蔡宪安. 五酯软胶囊在肾移植术后应用的临床研究(附60例报告)[J]. 器官移植, 2011, 2(5): 283-286.</mixed-citation></ref><ref id="hanspub.20661-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">朱兰, 王彼啸, 李娟, 等. 长期服用五酯胶囊减少他克莫司剂量对肾移植受者他克莫司药动学的影响[J]. 中华器官移植杂志, 2014, 35(9): 533-536.</mixed-citation></ref><ref id="hanspub.20661-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Iwata, H., Tezuka, K., Kadol, S., et al. (2004) Identification and Characterization of Potent CYP3A4 Inhibitors in Schisandra Fruit Extract. Drug Metabolism &amp; Disposition, 32, 1351-1358. &lt;br&gt;https://doi.org/10.1124/dmd.104.000646</mixed-citation></ref><ref id="hanspub.20661-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">张明华, 陈虹, 李灵芝, 等. 五味子甲素和五味子醇甲对四氯化碳所致肝脏损伤的保护作用[J]. 武警医学, 2002, 13(7): 395-396.</mixed-citation></ref></ref-list></back></article>